Treatment of Raynaud’s phenomenon: New insights and developments

被引：18
作者：
Ariane L. Herrick
机构：
[1] University of Manchester Rheumatic Diseases Centre, Hope Hospital, Salford
来源：
Current Rheumatology Reports | 2003年 / 5卷 / 2期
关键词：
Bosentan; Connective Tissue Growth Factor; Iloprost; Probucol; Systemic Sclerosis;
D O I：
10.1007/s11926-003-0046-0
中图分类号：
学科分类号：
摘要：
Although certain broad principles of treatment apply to all patients with Raynaud’s phenomenon, the exact approach will vary depending on the nature and severity of the underlying digital vascular problem. Advances in the understanding of the pathophysiology of Raynaud’s phenomenon are directing new lines of therapy. This review considers general (nonpharmacologic) measures, the different types of drug therapy, and the role of surgery. Recent advances in the use of more conventional treatments, such as calcium channel blockers, are discussed and also newer agents that are currently being researched, for example, endothelin-1 receptor antagonists and nitric oxide donors. The necessity of prompt assessment and treatment of acute digital ischemia, which is a medical emergency, is highlighted. © 2003, Current Science Inc.
引用
收藏
页码：168 / 174
页数：6
相关论文
共 50 条
[1]  
Block J.A., Sequeira W., Raynaud’s phenomenon, Lancet, 357, pp. 2042-2048, (2001)
[2]  
Harrison B.J., Silman A.J., Hider S., Herrick A.L., Cigarette smoking: a risk factor for digital vascular complications in systemic sclerosis, Arthritis Rheum, 46, pp. 3312-3316, (2002)
[3]  
Sari-Kouzel H., Hutchinson C.E., Middleton A., Et al., Foot problems in patients with systemic sclerosis, Rheumatology, 40, pp. 410-413, (2001)
[4]  
Comparison of sustained-release nifedipine and temperature biofeedback for treatment of primary Raynaud phenomenon: results from a randomized clinical trial with 1-year follow-up, Arch Intern Med, 160, pp. 1101-1108, (2000)
[5]  
Thompson A.E., Shea B., Welch V., Et al., Calcium-channel blockers for Raynaud’s phenomenon in systemic sclerosis, Arthritis Rheum, 44, pp. 1841-1847, (2001)
[6]  
Sturgill M.G., Seibold J.R., Rational use of calcium-channel antagonists in Raynaud’s phenomenon, Curr Op Rheumatol, 10, pp. 584-588, (1998)
[7]  
Mancini G.B., Henry G.C., Macaya C., Et al., Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study, Circulation, 94, pp. 258-265, (1996)
[8]  
Dziadzio M., Denton C.P., Smith R., Et al., Losartan therapy for Raynaud’s phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallelgroup, controlled trial, Arthritis Rheum, 42, pp. 2646-2655, (1999)
[9]  
Dahlof B., Devereux R.B., Kjeldsen S.E., Et al., Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol, Lancet, 359, pp. 995-1003, (2002)
[10]  
Flavahan N.A., Flavahan S., Liu Q., Et al., Increased alpha-2-adrenergic constriction of isolated arterioles in diffuse scleroderma, Arthritis Rheum, 43, pp. 1886-1890, (2000)
12345